Here's a look at some of the top Wall Street stories for medical device companies this week: FTC wants more data on Medtronic-Covidien deal, but analysts aren't worried; Greatbatch acquires Uruguay's CCC Medical Devices; T2 Biosystems IPO raises $57M for MRI-based diagnostics; Strong Q4, $750M buyback give CareFusion a boost; Baxano: Strong Q2, new patents can't appease Wall Street
Here's a look at some of the top regulatory stories for medical device companies this week: Valeant's hostile takeover hopes fade as Allergan war continues; Medtronic hires ex-Senators to lobby for Covidien deal; FTC wants more data on Medtronic-Covidien deal, but analysts aren't worried; St. Jude closes $200M NeuroTherm buy; Medtronic-Covidien merger means tax hit for all stockholders, including execs
Another Covidien shareholder sues to block the pending, $43 billion merger with Medtronic, arguing that the deal violates both American and Irish laws.
The terms of Medtronic's unusual $43 billion acquisition of Covidien means that all MDT shareholders are subject to paying a capital gains tax, including executives and board members.
Medtronic engages former Senators Trent Lott and John Breaux to lobby on behalf of the company's $43 billion acquisition of Covidien and its subsequent move overseas.
Medtech titan Medtronic (NYSE:MDT) has a few heavy-hitters in its corner during its fight against anti-corporate inversion measures on Capitol Hill.
Despite the furor on Capitol Hill, lawmakers aren't likely to produce reform that will hinder Medtronic's $43 billion acquisition of Covidien, according to Morgan Stanley analysts.
Here's a look at some of the top regulatory stories for medical device companies this week: Report: Medtech M&A exits don't hinge on FDA approval; White House rails against Medtronic-style corporate inversions; Smith & Nephew CEO: We've been an M&A target for 10 years; More mega-merger talk from medtech giants; Baxter sheds vaccines biz for $635M